Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Postepy Hig Med Dosw ; 55(1): 177-88, 2001.
Artigo em Polonês | MEDLINE | ID: mdl-11355531

RESUMO

The exocytosis of cytoplasmic granules plays a most important role in the regulation of many neutrophils functions: adhesion, phagocytosis, killing of bacteria and interaction with endothelial cells. Neutrophils contain following types of granules: azurophilic (primary) granules, specific (secondary) granules, gelatinase-rich tertiary granules and secretory vesicles. Neutrophil granules may be classified on the basis of their size, morphology, density or with reference to a given protein.


Assuntos
Grânulos Citoplasmáticos/classificação , Grânulos Citoplasmáticos/fisiologia , Neutrófilos/patologia , Neutrófilos/fisiologia , Adesão Celular/fisiologia , Exocitose/fisiologia , Humanos , Fagocitose/fisiologia
2.
Eur J Pharmacol ; 369(3): 313-7, 1999 Mar 26.
Artigo em Inglês | MEDLINE | ID: mdl-10225368

RESUMO

Although the selectivity and potency of adenosine amine congener (ADAC) at adenosine A1 receptors are similar to other highly selective agonists at this receptor type, the chemical structure of the N6 substituent is completely different. We now demonstrate that the characteristics of the therapeutic profile of ADAC are distinct from those observed during our previous studies of adenosine A1 receptor agonist-mediated neuroprotection. Most significantly, chronic treatment with low microgram doses of ADAC (25-100 microg/kg) protects against both mortality and neuronal damage induced by 10 min bilateral carotid occlusion in gerbils. At higher chronic doses, the statistical significance of the protective effect is lost. Acute preischemic administration of the drug at 75-200 microg/kg also results in a statistically significant reduction of postischemic mortality and morbidity. These data indicate that, contrary to other adenosine A1 receptor agonists whose chronic administration enhances postocclusive brain damage, ADAC may be a promising agent in treatment of both acute (e.g., cerebral ischemia) and chronic (seizures) disorders of the central nervous system in which adenosine A receptors appear to be involved.


Assuntos
Adenosina/análogos & derivados , Isquemia Encefálica/prevenção & controle , Agonistas do Receptor Purinérgico P1 , Adenosina/administração & dosagem , Adenosina/uso terapêutico , Análise de Variância , Animais , Isquemia Encefálica/tratamento farmacológico , Relação Dose-Resposta a Droga , Esquema de Medicação , Feminino , Gerbillinae , Hipocampo/efeitos dos fármacos , Injeções Intraperitoneais
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...